UK shareholder meetings calendar - next 7 days
19th Jun 2026 12:11
EDX Medical Group PLC - Cambridge, England-based developer of digital diagnostic products and services - Shares begin trading on AIM under the code EDX and are withdrawn from the Apex Segment of the Aquis Stock Exchange Growth Market. EDX announced its intent to move to AIM in April, when it applied under a "streamlined admission process" called the "AIM Designated Market" route intended for companies previously on Aquis. Read More
(Alliance News) - EDX Medical Group PLC on Monday shared plans to move its listing to London's AIM from the Aquis Exchange, alongside expectations of "record" revenue in financial 2026. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and Thursday and not separately reported by Alliance News: Read More
(Alliance News) - EDX Medical Group PLC on Monday announced a new GBP2 million subscription and convertible loan note deal with its founder and chief scientific officer. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - EDX Medical Group PLC on Friday said it has partnered with the NHS to develop a new pneumonia test for critically ill patients. Read More
(Alliance News) - EDX Medical Group PLC on Monday said it has signed an agreement with Spire Healthcare Group PLC to explore opportunities to utilise new diagnostic products and patient testing services. Read More
EDX Medical Group PLC - Cambridge, England-based firm that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Announces plans to launch a new "highly accurate" testicular cancer early detection test, which will be available "within weeks" in the UK. Says the TC100 assay, which analyses multiple specific tumour biomarkers and prepares a report for clinicians "using a proprietary AI-powered algorithm", "features exceptional sensitivity...and also detects cancer recurrences at ultra-high accuracy with 100% sensitivity following treatment and during ongoing surveillance of testicular cancer survivors". Says over 30 study reports have confirmed the assay's clinical accuracy and potential clinical usefulness in primary diagnosis, early detection, metastatic disease and recurrence of both seminoma and non-seminoma testicular cancer. Read More
EDX Medical Group PLC - Cambridge, England-based firm that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Signs master services agreement with Royal Marsden NHS Foundation Trust. The agreement will see EDX supply services to Royal Marsden over a three-year period. EDX Medical Founder & Chief Scientific Officer Chris Evans comments: "I am delighted EDX Medical has now been appointed as a supplier of diagnostic solutions and services to help serve the needs of one of the world's most eminent cancer hospitals." Read More
EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Pretax loss widens to GBP1.7 million in the six months to September 30 from GBP1.3 million a year prior. Revenue falls to GBP17.8 million from GBP20.1 million, administrative expenses increase to GBP1.7 million from GBP1.3 million. Read More
(Alliance News) - EDX Medical Group PLC on Wednesday said that it has signed an exclusive distribution agreement with mirdetect GmbH to distribute its M371 testicular cancer diagnostic test. Read More
EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Says it expects to record revenue growth beginning in its fourth quarter ending March 31, noting the "pipeline of additional products in development continues to expand, underpinning future continued growth". Adds that EDX management is exploring "point of care and laboratory testing solutions" at both its own labs and with others in the life sciences sector. Says in addition to recently announced distribution agreements with Caris Life Sciences Inc and Curesponse, will later this month will bring to market a "comprehensive hereditary genetic risk testing products and services, for cancer and heart disease". Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Wednesday and Tuesday and not separately reported by Alliance News: Read More
EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Signs in-licensing agreement with Oxford University patent portfolio manager Oxford University Innovation Ltd. Agreement to allow EDX access to intellectual property funded by Cancer Research UK and developed at Oxford and Birmingham Universities. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More